Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

The publisher's Medical Devices sector report, "Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update' provides comprehensive information about the Next Generation Sequencing (NGS) Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Next generation sequencing (NGS) refers to high-throughput methods for DNA sequencing that are not Sanger-based.

Scope

• Extensive coverage of the Next Generation Sequencing (NGS) Tests under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Next Generation Sequencing (NGS) Tests and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment/industry

Reasons to Buy

The report enables you to:

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of Next Generation Sequencing (NGS) Tests under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Next Generation Sequencing (NGS) Tests Overview

3 Products under Development

3.1 Next Generation Sequencing (NGS) Tests - Pipeline Products by Stage of Development

3.2 Next Generation Sequencing (NGS) Tests - Pipeline Products by Territory

3.3 Next Generation Sequencing (NGS) Tests - Pipeline Products by Regulatory Path

3.4 Next Generation Sequencing (NGS) Tests - Pipeline Products by Estimated Approval Date

3.5 Next Generation Sequencing (NGS) Tests - Ongoing Clinical Trials

4 Next Generation Sequencing (NGS) Tests - Pipeline Products under Development by Companies

4.1 Next Generation Sequencing (NGS) Tests Companies - Pipeline Products by Stage of Development

4.2 Next Generation Sequencing (NGS) Tests - Pipeline Products by Stage of Development

5 Next Generation Sequencing (NGS) Tests Companies and Product Overview

6 Appendix

6.1 Methodology

6.2 About the Publisher

6.3 Contact the Publisher

6.4 Disclaimer

Companies Mentioned

• AccuraGen Inc
• ACT Genomics Co LTD
• Adaptive Biotechnologies Corp
• Almac Diagnostic Services Ltd
• Amoy Diagnostics Co Ltd
• AnchorDx Medical Co Ltd
• ArcherDx Inc
• Berry Oncology Corp
• BGI Genomics Co Ltd
• Biocartis Group NV
• Biodesix Inc
• BioLink
• bioTheranostics Inc
• Boston University
• Buhlmann Laboratories AG
• Burning Rock Biotech Ltd
• Cardiff Oncology Inc
• Cerba HealthCare SAS
• DCGen Co Ltd
• DiaGyn Ltd
• Eiken Chemical Co Ltd
• Epic Sciences Inc
• Epigenomics AG
• First Genetics JCS
• Flomics Biotech
• Foundation Medicine Inc
• Freenome Inc
• Gencurix Co., Ltd.
• Geneseeq Technology Inc
• Genetron Health (Beijing) Co Ltd
• Genomic Health Inc
• GigaGen Inc
• HTG Molecular Diagnostics Inc
• Illumina Inc
• Immunovia AB
• Inivata Ltd
• Insight Genetics Inc
• InVivoScribe Technologies Inc
• IvyGene Diagnostics
• Laboratory Corp of America Holdings
• Lucence Diagnostics Pte Ltd
• Mega Genomics Ltd
• MolecularMD Corp
• Myriad Genetics Inc
• NGeneBio Co Ltd
• Novigenix SA
• Novomics Co Ltd
• NuGEN Technologies Inc
• NuProbe Global
• OncoDNA SA
• OncoSpire Genomics
• OncXerna Therapeutics Inc
• OrigiMed Inc
• Otsuka Medical Devices Co Ltd
• Pasteur Institute
• Personal Genome Diagnostics Inc
• Pillar Biosciences Inc
• Predictive Biosciences Inc (Inactive)
• Qiagen NV
• Quantgene Inc
• RealSeq Biosciences Inc
• Rhodx Inc
• Roche Diagnostics International Ltd
• Silicon Biosystems S.p.A.
• Sophia Genetics SA
• Spectrum Solutions LLC
• Sysmex Corp
• Sysmex Inostics GmbH
• Tempus Health Inc
• Thermo Fisher Scientific Inc
• Trivitron Healthcare Pvt Ltd
• TwinStrand Biosciences Inc
• University of Chicago
• University of Michigan Rogel Cancer Center
• University of Texas Health Science Center at Houston
• Vyant Bio Inc

For more information about this report visit https://www.researchandmarkets.com/r/kwwt24